Since the first China International Import Expo (CIIE) was held in 2018, nearly 200 companies and institutions have attended the event for nine consecutive years.
These "full-attendance" exhibitors showcase a steady stream of major debuts and first-time showcases, which most directly reflects their deep cultivation of the Chinese market.
At the same time, their renewal across nine editions serves as the best testament to the surging vitality of the Chinese market.
The technical equipment exhibition area at the ninth CIIE is seen on November 5.
Schneider Electric, a veteran energy technology giant, has attended the CIIE nine times, continuously witnessing and supporting the digital, intelligent, and green transformation of traditional industries such as oil, gas, and chemicals in China.
This year, the longtime CIIE friend is focusing not only on traditional industries but even more on emerging sectors represented by data centers, bringing a full-stack AI data center solution for ultra-large GPU clusters as well as a power management native intelligent agent making its debut at this year's CIIE.
Yin Zheng, Executive Vice President of Schneider Electric and President of China and East Asia, said that data centers are one of the core segments of China's new infrastructure and are becoming an important growth engine for Schneider Electric's business in China.
On November 4, staff members made preparations at the Schneider Electric booth in the technical equipment exhibition area of the ninth CIIE.
"CIIE babies" are a hot topic each year in the medical exhibition area of the CIIE.
The term refers to innovative drugs and medical devices that first appear at the CIIE and then accelerate toward approval and clinical application in China.
GlaxoSmithKline PLC (GSK), also a nine-time full-attendance exhibitor, said that about nine new products or new indications are expected to be approved in China over the next three years.
At the same time, GSK for the first time systematically presented at this year's CIIE a complete picture of its upgraded China strategy, focusing on full-chain prevention, treatment, rehabilitation, and management services in key areas such as hepatitis B prevention and treatment, adult immunization, and respiratory disease management, fulfilling its firm commitment to advancing together with "Healthy China."
Zhao Lun, Vice President of GSK and Head of Corporate Communications and Government Affairs in China, told reporters, "We have found that the value of the CIIE is constantly becoming more prominent, from displaying innovation and products to expanding our circle of friends, continuously discussing our health upgrades and innovation accessibility, and jointly promoting the development of the ecosystem."
GSK for the first time systematically presented at this year's CIIE a complete picture of its upgraded China strategy.
This year, Shiseido unveiled more than 60 new products at the CIIE for the first time, covering diverse categories from daily skincare to fashion beauty.
In addition, its hair regeneration medical technology, developed over nearly a decade, also made its debut at the CIIE, and the company used the occasion to reach a strategic cooperation with Qiyan Hospital in the Hainan Boao Lecheng Pilot Zone to explore clinical validation and commercial application of this technology in China.
From bringing global products into China to jointly innovating with medical institutions and industry partners around local demand, the Chinese market is becoming an important stop for multinational beauty companies to validate new technologies and explore new models.
Ge Fei, Pharmaceutical Affairs Director of Shiseido (China) Investment Co., Ltd., said that Shiseido has a Chinese R&D team and supplier team to create a series of products specifically for the needs of Chinese consumers, including cosmetics, medical devices, and post-medical-aesthetic skin repair products, covering care and management across the full skin cycle.
Shiseido's hair regeneration medical technology, developed over nearly a decade, made its debut at this year's CIIE.
Comments